Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) and Protagonist Therapeutics (NASDAQ:PTGX – Get Free Report) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, earnings, risk and profitability.
Insider & Institutional Ownership
86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 18.1% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Atea Pharmaceuticals and Protagonist Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Atea Pharmaceuticals | 1 | 0 | 0 | 1 | 2.50 |
| Protagonist Therapeutics | 1 | 1 | 13 | 0 | 2.80 |
Profitability
This table compares Atea Pharmaceuticals and Protagonist Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Atea Pharmaceuticals | N/A | -46.34% | -42.52% |
| Protagonist Therapeutics | -282.83% | -19.89% | -18.40% |
Valuation and Earnings
This table compares Atea Pharmaceuticals and Protagonist Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Atea Pharmaceuticals | N/A | N/A | -$158.35 million | ($1.94) | -2.85 |
| Protagonist Therapeutics | $46.02 million | 146.82 | -$130.15 million | ($2.05) | -51.65 |
Protagonist Therapeutics has higher revenue and earnings than Atea Pharmaceuticals. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Atea Pharmaceuticals has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.12, suggesting that its stock price is 112% more volatile than the S&P 500.
Summary
Protagonist Therapeutics beats Atea Pharmaceuticals on 9 of the 14 factors compared between the two stocks.
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
